Luseogliflozin (BioDeep_00000676761)
代谢物信息卡片
Luseogliflozin
化学式: C23H30O6S (434.1763)
中文名称: 鲁格列净
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC1=CC=C(C=C1)CC2=CC(=C(C=C2C)OC)C3C(C(C(C(S3)CO)O)O)O
InChI: InChI=1S/C23H30O6S/c1-4-29-16-7-5-14(6-8-16)10-15-11-17(18(28-3)9-13(15)2)23-22(27)21(26)20(25)19(12-24)30-23/h5-9,11,19-27H,4,10,12H2,1-3H3/t19-,20-,21+,22-,23+/m1/s1
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BK - Sodium-glucose co-transporter 2 (sglt2) inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
C471 - Enzyme Inhibitor > C98083 - SGLT2 Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:134725
- PubChem: 11988953
- DrugBank: DB12214
- ChEMBL: CHEMBL1093423
- CAS: 898537-18-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Kentaro Ejiri, Toru Miyoshi, Hajime Kihara, Yoshiki Hata, Toshihiko Nagano, Atsushi Takaishi, Hironobu Toda, Seiji Namba, Yoichi Nakamura, Satoshi Akagi, Satoru Sakuragi, Taro Minagawa, Yusuke Kawai, Nobuhiro Nishii, Soichiro Fuke, Masaki Yoshikawa, Kazufumi Nakamura, Hiroshi Ito. Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure.
Scientific reports.
2022 09; 12(1):15449. doi:
10.1038/s41598-022-19371-6. [PMID: 36104378] - Yukihiro Chino, Masanari Kuwabara, Ichiro Hisatome. Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
Journal of clinical pharmacology.
2022 03; 62(3):366-375. doi:
10.1002/jcph.1970. [PMID: 34545949] - Mitsutaka Nakashima, Toru Miyoshi, Kentaro Ejiri, Hajime Kihara, Yoshiki Hata, Toshihiko Nagano, Atsushi Takaishi, Hironobu Toda, Seiji Nanba, Yoichi Nakamura, Satoshi Akagi, Satoru Sakuragi, Taro Minagawa, Yusuke Kawai, Nobuhiro Nishii, Soichiro Fuke, Masaki Yoshikawa, Kazufumi Nakamura, Hiroshi Ito. Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction.
ESC heart failure.
2022 02; 9(1):712-720. doi:
10.1002/ehf2.13683. [PMID: 35267246] - Shaoxun Wang, Feng Jiao, Jane J Border, Xing Fang, Reece F Crumpler, Yedan Liu, Huawei Zhang, Joshua Jefferson, Ya Guo, Parker S Elliott, Kirby N Thomas, Luke B Strong, Austin H Urvina, Baoying Zheng, Arjun Rijal, Stanley V Smith, Hongwei Yu, Richard J Roman, Fan Fan. Luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, reverses cerebrovascular dysfunction and cognitive impairments in 18-mo-old diabetic animals.
American journal of physiology. Heart and circulatory physiology.
2022 02; 322(2):H246-H259. doi:
10.1152/ajpheart.00438.2021. [PMID: 34951541] - Hideaki Jinnouchi, Akira Yoshida, Hiromi Tsuyuno, Kiyoko Iwamoto, Seigo Sugiyama, Kunio Hieshima, Keizo Kajiwara, Noboru Kurinami, Tomoko Suzuki, Katsunori Jinnouchi, Tomio Jinnouchi. Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin.
Diabetes research and clinical practice.
2021 Dec; 182(?):108916. doi:
10.1016/j.diabres.2021.108916. [PMID: 34119556] - Anqi Zhang, Daisuke Nakano, Wararat Kittikulsuth, Yuka Yamashita, Akira Nishiyama. Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice.
International journal of molecular sciences.
2021 Jul; 22(15):. doi:
10.3390/ijms22158169. [PMID: 34360935] - Daisuke Inoue, Hiroshi Nishi, Reiko Inoue, Masaomi Nangaku. Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
International heart journal.
2021; 62(3):592-600. doi:
10.1536/ihj.20-716. [PMID: 34054000] - Hiroyuki Ito, Suzuko Matsumoto, Takuma Izutsu, Eiji Kusano, Jiro Kondo, Hideyuki Inoue, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori, Michiko Togane. Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation.
PloS one.
2021; 16(3):e0248577. doi:
10.1371/journal.pone.0248577. [PMID: 33720983] - Kentaro Kohagura, Hironori Yamasaki, Hiroki Takano, Yusuke Ohya, Yutaka Seino. Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes.
Hypertension research : official journal of the Japanese Society of Hypertension.
2020 09; 43(9):876-883. doi:
10.1038/s41440-020-0426-0. [PMID: 32203453] - Daisuke Yamazaki, Yoshio Konishi, Takashi Morikawa, Hideki Kobara, Tsutomu Masaki, Hirofumhi Hitomi, Kenji Osafune, Daisuke Nakano, Wararat Kittikulsuth, Akira Nishiyama. Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
Journal of diabetes investigation.
2020 Jul; 11(4):834-843. doi:
10.1111/jdi.13205. [PMID: 31880858] - F Anthony Romero, Christopher T Jones, Yingzi Xu, Martijn Fenaux, Randall L Halcomb. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Journal of medicinal chemistry.
2020 05; 63(10):5031-5073. doi:
10.1021/acs.jmedchem.9b01701. [PMID: 31930920] - Jun Shirakawa, Kazuki Tajima, Tomoko Okuyama, Mayu Kyohara, Yu Togashi, Dario F De Jesus, Giorgio Basile, Tatsuya Kin, A M James Shapiro, Rohit N Kulkarni, Yasuo Terauchi. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway.
Diabetologia.
2020 03; 63(3):577-587. doi:
10.1007/s00125-019-05071-w. [PMID: 31897526] - Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad, M Shahar Yar. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
European journal of medicinal chemistry.
2019 Dec; 184(?):111773. doi:
10.1016/j.ejmech.2019.111773. [PMID: 31630053] - Yoshishige Samukawa, Masakazu Haneda, Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Yusuke Kubo, Yuri Sato, Soichi Sakai. Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.
Clinical pharmacology in drug development.
2018 11; 7(8):820-828. doi:
10.1002/cpdd.456. [PMID: 29693800] - Yifan Zhang, Daisuke Nakano, Yu Guan, Hirofumi Hitomi, Akiyoshi Uemura, Tsutomu Masaki, Hideki Kobara, Takeshi Sugaya, Akira Nishiyama. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
Kidney international.
2018 09; 94(3):524-535. doi:
10.1016/j.kint.2018.05.002. [PMID: 30045814] - Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Hisae Imazeki, Hidekazu Ochiai, Soichi Sakai. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
Current medical research and opinion.
2018 06; 34(6):981-994. doi:
10.1080/03007995.2018.1441816. [PMID: 29448833] - Yutaka Seino, Daisuke Yabe, Takashi Sasaki, Atsushi Fukatsu, Hisae Imazeki, Hidekazu Ochiai, Soichi Sakai. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
Journal of diabetes investigation.
2018 Mar; 9(2):332-340. doi:
10.1111/jdi.12694. [PMID: 28502112] - Takashi Shibuya, Nobutoshi Fushimi, Miyuka Kawai, Yohei Yoshida, Hiroki Hachiya, Shun Ito, Hiromi Kawai, Noritsugu Ohashi, Akihiro Mori. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study.
Diabetes, obesity & metabolism.
2018 02; 20(2):438-442. doi:
10.1111/dom.13061. [PMID: 28719078] - Yoshishige Samukawa, Michio Sata, Kenichi Furihata, Toshifumi Ito, Naohiko Ueda, Hidekazu Ochiai, Soichi Sakai, Yuji Kumagai. Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.
Clinical pharmacology in drug development.
2017 Sep; 6(5):439-447. doi:
10.1002/cpdd.364. [PMID: 28783873] - Yusuke Nakatsu, Hiroki Kokubo, Batmunkh Bumdelger, Masao Yoshizumi, Takeshi Yamamotoya, Yasuka Matsunaga, Koji Ueda, Yuki Inoue, Masa-Ki Inoue, Midori Fujishiro, Akifumi Kushiyama, Hiraku Ono, Hideyuki Sakoda, Tomoichiro Asano. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
International journal of molecular sciences.
2017 Aug; 18(8):. doi:
10.3390/ijms18081704. [PMID: 28777298] - Daisuke Yabe, Masahiro Iwasaki, Hitoshi Kuwata, Takuya Haraguchi, Yoshiyuki Hamamoto, Takeshi Kurose, Kiminobu Sumita, Hitoshi Yamazato, Shigeto Kanada, Yutaka Seino. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
Diabetes, obesity & metabolism.
2017 05; 19(5):739-743. doi:
10.1111/dom.12848. [PMID: 27990776] - Tsuneo Takenaka, Miyako Kishimoto, Mari Ohta, Osamu Tomonaga, Hiromichi Suzuki. Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.
Diabetes & vascular disease research.
2017 05; 14(3):258-261. doi:
10.1177/1479164117690299. [PMID: 28467199] - Yukihiro Chino, Masatoshi Hasegawa, Yoshiki Fukasawa, Yoko Mano, Kagumi Bando, Atsunori Miyata, Yasuhiro Nakai, Hiromi Endo, Jun-Ichi Yamaguchi. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Xenobiotica; the fate of foreign compounds in biological systems.
2017 Apr; 47(4):314-323. doi:
10.1080/00498254.2016.1193913. [PMID: 27324291] - Atsunori Miyata, Masatoshi Hasegawa, Kenji Hachiuma, Haruyuki Mori, Nobuko Horiuchi, Akiko Mizuno-Yasuhira, Yukihiro Chino, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa, Yasuhiro Nakai, Jun-Ichi Yamaguchi. Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.
Xenobiotica; the fate of foreign compounds in biological systems.
2017 Apr; 47(4):332-345. doi:
10.1080/00498254.2016.1193263. [PMID: 27347703] - Ryotaro Bouchi, Masahiro Terashima, Yuriko Sasahara, Masahiro Asakawa, Tatsuya Fukuda, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto, Yoshihiro Ogawa. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study.
Cardiovascular diabetology.
2017 03; 16(1):32. doi:
10.1186/s12933-017-0516-8. [PMID: 28253918] - Shinji Kobuchi, Megumi Matsuno, Momoko Kawamoto, Naoto Kojima, Yukako Ito, Masayuki Yamashita, Toshiyuki Sakaeda. A simple and rapid LC-MS/MS method for quantitation of luseogliflozin in rat plasma and its application to a PK study.
Bioanalysis.
2017 Jan; 9(2):163-171. doi:
10.4155/bio-2016-0188. [PMID: 27960548] - Takahiro Tosaki, Hideki Kamiya, Tatsuhito Himeno, Yoshiro Kato, Masaki Kondo, Kaori Toyota, Tomoyo Nishida, Megumi Shiroma, Kaori Tsubonaka, Hitomi Asai, Miho Moribe, Yuki Nakaya, Jiro Nakamura. Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.
Internal medicine (Tokyo, Japan).
2017; 56(6):597-604. doi:
10.2169/internalmedicine.56.7196. [PMID: 28321056] - Yoshishige Samukawa, Masaru Mutoh, Shi Chen, Nobuo Mizui. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
Biological & pharmaceutical bulletin.
2017; 40(8):1207-1218. doi:
10.1248/bpb.b16-00998. [PMID: 28769002] - Yoshishige Samukawa, Hirohisa Omiya, Hirotaka Watase, Kazunari Nozaki, Soichi Sakai, Rimei Nishimura. Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.
Advances in therapy.
2016 07; 33(7):1215-30. doi:
10.1007/s12325-016-0350-5. [PMID: 27255763] - Soichi Sakai, Kohei Kaku, Yutaka Seino, Nobuya Inagaki, Masakazu Haneda, Takashi Sasaki, Atsushi Fukatsu, Haruka Kakiuchi, Yoshishige Samukawa. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
Clinical therapeutics.
2016 Apr; 38(4):843-862.e9. doi:
10.1016/j.clinthera.2016.01.017. [PMID: 27021608] - Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Journal of pharmacological sciences.
2016 Mar; 130(3):159-69. doi:
10.1016/j.jphs.2016.02.003. [PMID: 26970780] - Seizo Okauchi, Masashi Shimoda, Atsushi Obata, Tomohiko Kimura, Hidenori Hirukawa, Kenji Kohara, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.
Biochemical and biophysical research communications.
2016 Feb; 470(3):772-782. doi:
10.1016/j.bbrc.2015.10.109. [PMID: 26505796] - Masakazu Haneda, Yutaka Seino, Nobuya Inagaki, Kohei Kaku, Takashi Sasaki, Atsushi Fukatsu, Haruka Kakiuchi, Yuri Sato, Soichi Sakai, Yoshishige Samukawa. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Clinical therapeutics.
2016 Jan; 38(1):66-88.e20. doi:
10.1016/j.clinthera.2015.10.025. [PMID: 26718606] - Teisuke Takahashi, Koji Yamamoto. [Pharmacological and clinical profile of a new SGLT2 inhibitor, luseogliflozin (Lusefi®)].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica.
2015 Sep; 146(3):150-8. doi:
10.1254/fpj.146.150. [PMID: 26354015] - Saeko Uchida, Akiko Mitani, Emi Gunji, Teisuke Takahashi, Koji Yamamoto. In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: Inhibition kinetics and binding studies.
Journal of pharmacological sciences.
2015 May; 128(1):54-7. doi:
10.1016/j.jphs.2015.04.001. [PMID: 26003086] - Takashi Sasaki, Yutaka Seino, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa. Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
Advances in therapy.
2015 Apr; 32(4):319-40. doi:
10.1007/s12325-015-0200-x. [PMID: 25855342] - Kalliopi Pafili, Nikolaos Papanas. Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?.
Expert opinion on pharmacotherapy.
2015 Mar; 16(4):453-6. doi:
10.1517/14656566.2015.994505. [PMID: 25605060] - Yuji Kumagai, Tomoko Hasunuma, Soichi Sakai, Hidekazu Ochiai, Yoshishige Samukawa. Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.
PloS one.
2015; 10(10):e0139873. doi:
10.1371/journal.pone.0139873. [PMID: 26444986] - Masatoshi Hasegawa, Yukihiro Chino, Nobuko Horiuchi, Kenji Hachiuma, Masahiro Ishida, Yoshiki Fukasawa, Yasuhiro Nakai, Jun-ichi Yamaguchi. Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.
Xenobiotica; the fate of foreign compounds in biological systems.
2015; 45(12):1105-15. doi:
10.3109/00498254.2015.1042947. [PMID: 26489961] - L Zanoli, A Granata, P Lentini, S Rastelli, P Fatuzzo, F Rapisarda, P Castellino. Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.
TheScientificWorldJournal.
2015; 2015(?):317507. doi:
10.1155/2015/317507. [PMID: 25785281] - Yutaka Seino, Kohei Kaku, Nobuya Inagaki, Masakazu Haneda, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Endocrine journal.
2015; 62(7):593-603. doi:
10.1507/endocrj.ej15-0097. [PMID: 25971406] - Yutaka Seino. Luseogliflozin for the treatment of type 2 diabetes.
Expert opinion on pharmacotherapy.
2014 Dec; 15(18):2741-9. doi:
10.1517/14656566.2014.978290. [PMID: 25359155] - Yukihiro Chino, Yoshishige Samukawa, Soichi Sakai, Yasuhiro Nakai, Jun-ichi Yamaguchi, Takeo Nakanishi, Ikumi Tamai. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Biopharmaceutics & drug disposition.
2014 Oct; 35(7):391-404. doi:
10.1002/bdd.1909. [PMID: 25044127] - Akiko Mizuno-Yasuhira, Yasuhiro Nakai, Emi Gunji, Saeko Uchida, Teisuke Takahashi, Kohnosuke Kinoshita, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa, Jun-Ichi Yamaguchi. A Strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2014 Sep; 42(9):1456-65. doi:
10.1124/dmd.114.058305. [PMID: 25005603] - Go Woon Kim, Sung Hyun Chung. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Archives of pharmacal research.
2014 Aug; 37(8):957-66. doi:
10.1007/s12272-014-0419-0. [PMID: 24950857] - Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Soichi Sakai, Yoshishige Samukawa. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.
Current medical research and opinion.
2014 Jul; 30(7):1219-30. doi:
10.1185/03007995.2014.901943. [PMID: 24597840] - Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.
Current medical research and opinion.
2014 Jul; 30(7):1231-44. doi:
10.1185/03007995.2014.909390. [PMID: 24673496] - Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.
Current medical research and opinion.
2014 Jul; 30(7):1245-55. doi:
10.1185/03007995.2014.912983. [PMID: 24708292] - Takashi Sasaki, Yutaka Seino, Atsushi Fukatsu, Soichi Sakai, Yoshishige Samukawa. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.
Advances in therapy.
2014 Mar; 31(3):345-61. doi:
10.1007/s12325-014-0102-3. [PMID: 24535625] - Naoki Kojima, Jan M Williams, Teisuke Takahashi, Noriyuki Miyata, Richard J Roman. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
The Journal of pharmacology and experimental therapeutics.
2013 Jun; 345(3):464-72. doi:
10.1124/jpet.113.203869. [PMID: 23492941] - K Yamamoto, S Uchida, K Kitano, N Fukuhara, L Okumura-Kitajima, E Gunji, A Kozakai, H Tomoike, N Kojima, J Asami, H Toyoda, M Arai, T Takahashi, K Takahashi. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
British journal of pharmacology.
2011 Sep; 164(1):181-91. doi:
10.1111/j.1476-5381.2011.01340.x. [PMID: 21410690]